Similar articles

• Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants.

  Wilkins D, Yuan Y, Chang Y, Aksyuk AA, Núñez BS, Wählby-Hamrén U, Zhang T, Abram ME, Leach A, Villafana T, Esser MT. Wilkins D, et al. Nat Med. 2023 May;29(5):1172-1179. doi: 10.1038/s41591-023-02316-5. Epub 2023 Apr 24. Nat Med. 2023. PMID: 37095249 Free PMC article.
• Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.

  Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Griffin MP, et al. N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556. N Engl J Med. 2020. PMID: 32726528 Clinical Trial.
• Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.

  Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Hammitt LL, et al. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. N Engl J Med. 2022. PMID: 35235726 Clinical Trial.
• The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis.

  Turalde-Mapili MWR, Mapili JAL, Turalde CWR, Pagcatipunan MR. Turalde-Mapili MWR, et al. Front Pediatr. 2023 Apr 4;11:1132740. doi: 10.3389/fped.2023.1132740. eCollection 2023. Front Pediatr. 2023. PMID: 37082704 Free PMC article. Review.
• Nirsevimab: First Approval.

  Keam SJ. Keam SJ. Drugs. 2023 Feb;83(2):181-187. doi: 10.1007/s40265-022-01829-6. Drugs. 2023. PMID: 36577878 Review.